NCT05458401
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Not yet recruiting
Drug Category: Therapeutic Antibody
Key Eligibility Criteria:
Gender: All
Age: Child, Adult, Older Adult
Location of Metastases: Brain
Additional Notes: Patients must have received 2 or more prior anti-HER2-based regimens
Exclusions:
https://ClinicalTrials.gov/show/NCT05458401